


Atorvastatin/Ezetimibe beats atorvastatin after PCI

29 July 2015



More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according to a study published in the Aug. 4 issue of the *Journal of the American College of Cardiology*.

Kenichi Tsujita, Ph.D., from Kumamoto University in Japan, and colleagues examined the effects of ezetimibe plus atorvastatin versus atorvastatin monotherapy on <u>lipid profiles</u> and <u>coronary</u> <u>atherosclerosis</u> in a randomized trial involving Japanese patients who underwent PCI.

The researchers found that, compared with atorvastatin monotherapy, the combination of atorvastatin/ezetimibe resulted in lower levels of low-density-lipoprotein cholesterol (63.2 ± 16.3 mg/dL versus 73.3 ± 20.3 mg/dL; P

"Compared with standard statin monotherapy, the combination of statin plus ezetimibe showed greater coronary plaque regression, which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.



APA citation: Atorvastatin/Ezetimibe beats atorvastatin after PCI (2015, July 29) retrieved 17 June 2022 from https://medicalxpress.com/news/2015-07-atorvastatinezetimibe-atorvastatin-pci.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.